Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of the same outcome after introduction of Havrixâ„¢ in Panama.
In this study, systematic review of the databases of epidemiologic surveillance system (Ministry of Health), for hepatitis related outcomes will be performed. The analysis will be performed by age group, years and country region.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hepatitis Cohort | Subjects suffering with hepatitis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Epidemiologic Surveillance System of the Ministry of Health of Panama | Other | Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of reported hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) | In post vaccine introduction period (2008-2010) compared to pre-vaccination period (2000-2007) |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by year | From year 2000 until year 2010 | |
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by age groups | From year 2000 until year 2010 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The target population to be studied will be all subjects reported with hepatitis related outcomes to the Epidemiologic Surveillance System of the Ministry of Health of Panama, between 2000 and 2010.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Clayton | Provincia de Panamá | Panama |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25981490 | Derived | Estripeaut D, Contreras R, Tinajeros O, Castrejon MM, Shafi F, Ortega-Barria E, DeAntonio R. Impact of Hepatitis A vaccination with a two-dose schedule in Panama: Results of epidemiological surveillance and time trend analysis. Vaccine. 2015 Jun 22;33(28):3200-7. doi: 10.1016/j.vaccine.2015.04.100. Epub 2015 May 14. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006505 | Hepatitis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
No samples retained
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by region | From year 2000 until year 2010 |